ArticleBlood2023

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.

Deyi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.